To print: Select File and then Print from your browser's menu

Title: Ropinirole Prolonged-Release Delivery System Reduces Off Time and Improves Motor Symptoms in Advanced Parkinson's Disease: Presented at ANA

"Ropinirole Prolonged-Release Delivery System Reduces Off Time and Improves Motor Symptoms in Advanced Parkinson's Disease: Presented at ANA"

By Maggie Schwarz WASHINGTON, DC -- October 11, 2007 -- In a trial of patients with advanced Parkinson's disease who were not optimally controlled with levodopa, prolonged-release ropinirole significantly reduced off time, and improved motor symptoms, according to research presented here at the 132nd Annual Meeting of the American Neurological Association (ANA). Researchers enrolled patients with Parkinson's disease who were not controlled optimally with levodopa and randomised 202 patients to adjunctive treatment with prolonged-release ropinirole and 191 to placebo. Treatment was administered once daily for 24 weeks. Lead author Rajesh Pahwa, MD, Director, Parkinson's Disease and Movement Disorder Center, and Laverne and Joyce Rider Professor of Neurology, University of Kansas School of Medicine, Kansas City, Kansas, United States, presented the study results in a poster session on. The initial dose of ropinirole was 2.0 mg daily and was titrated to a maximum of 24.0 mg daily. At 8.0 mg daily and at each subsequent increase, levodopa dose reduction was required. The primary endpoint was a mean change in daily off time at week 24 (last observation carried forward [LOCF]). [Post hoc analyses assessed mean changes from baseline in tremor, rigidity, and bradykinesia components of the Unified Parkinson's Disease Rating Scale (UPDRS) at week 24 LOCF.

Prolonged-release ropinirole reduced daily off time significantly compared with placebo at week 24 LOCF (P <.0001). At week 24 LOCF, significantly greater improvements were seen with ropinirole 24-hour compared with placebo, for changes in tremor (P =.0001), rigidity (P =.0003) and bradykinesia (P <.0001) from baseline.

Mean dose of ropinirole at the last assessment was 18.8 mg +- 6.3 mg daily.

Dr. Pahwa concluded that the dopamine agonist ropinirole, in a prolonged-release formulation, can improve difficult-to-control symptoms of advanced Parkinson's disease, a stage of the disease notable for suboptimal control using levodopa.

[Presentation title: Adjunctive Ropinirole 24-Hour Prolonged Release Reduced "Off" Time and Improves the Cardinal Symptoms of Tremor, Rigidity, and Bradykinesia in Patients With Advanced Parkinson's Disease (PD). Poster 2]

Copyright © 2009 P\S\L Consulting Group Inc. All rights reserved. Republication or redistribution of P\S\L content is expressly prohibited without the prior written consent of P\S\L. P\S\L shall not be liable for any errors, omissions or delays in this content or any other content on its sites, newsletters or other publications, nor for any decisions or actions taken in reliance on such content.